Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.35 |
| ▸ | CA12 | O43570 | 3/20 | 0.34 |
| ▸ | CA1 | P00915 | 3/20 | 0.34 |
| ▸ | CA9 | Q16790 | 3/20 | 0.34 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.34 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 3/20 | 0.33 |
| ▸ | TTR | P02766 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
| ▸ | PPARA | Q07869 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17786202 | 0.85 | DRD2 (0.36) | DRD2CYP2C9CA12CA1CA9 | |
| SCHEMBL17786208 | 0.84 | PTGDR2 (0.39) | DRD2CA12CA1CA9MEN1 | |
| SCHEMBL17784730 | 0.83 | MAPT (0.38) | DRD2CA12CA1CA9SMN1; SMN2 | |
| SCHEMBL17786198 | 0.83 | IDO1 (0.34) | DRD2CA12CA1CA9PDCD1 | |
| SCHEMBL17786199 | 0.80 | IDO1 (0.38) | CYP2C9CYP1A2PPARGPPARAALDH1A1 | |
| SCHEMBL13745985 | 0.79 | ALDH1A1 (0.40) | DRD2CA12CA1CA9TSHR | |
| SCHEMBL6943654 | 0.78 | CYP4F2 (0.36) | DRD2CA12CA1CA9PDCD1 | |
| SCHEMBL30039264 | 0.78 | CYP4F2 (0.36) | DRD2CA12CA1CA9PDCD1 | |
| SCHEMBL17784694 | 0.78 | MAPT (0.35) | DRD2CA12CA1CA9SMN1; SMN2 | |
| SCHEMBL13746429 | 0.77 | CA12 (0.30) | CA12CA1CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107001309-B | Bis (sulfonamide) derivatives and their use as MPGES inhibitors | 格辛塔制药公司 | 2021-03-05 | — | — | CN | disclosed |
| EP-3224253-B1 | BIS (SULFONAMIDE) DERIVATIVES AND THEIR USE AS MPGES INHIBITORS | GESYNTA PHARMA AB (SE) | 2019-10-30 | — | — | EP | disclosed |
| US-10081614-B2 | Bis(sulfonamide) derivatives and their use as mPGES inhibitors | ACTURUM REAL ESTATE AB (SE) | 2018-09-25 | — | — | US | disclosed |
| US-20170313672-A1 | BIS(SULFONAMIDE) DERIVATIVES AND THEIR USE AS MPGES INHIBITORS | GESYNTA PHARMA AB (SE) | 2017-11-02 | — | — | US | disclosed |
| US-20170313672-A1 | BIS(SULFONAMIDE) DERIVATIVES AND THEIR USE AS MPGES INHIBITORS | GESYNTA PHARMA AB (SE) | 2017-11-02 | — | — | US | disclosed |
| US-20170313672-A1 | BIS(SULFONAMIDE) DERIVATIVES AND THEIR USE AS MPGES INHIBITORS | GESYNTA PHARMA AB (SE) | 2017-11-02 | — | — | US | disclosed |
| EP-3224253-A1 | BIS(SULFONAMIDE) DERIVATIVES AND THEIR USE AS MPGES INHIBITORS | Acturum Real Estate AB (SE) | 2017-10-04 | — | — | EP | disclosed |
| WO-2016085392-A1 | BIS(SULFONAMIDE) DERIVATIVES AND THEIR USE AS MPGES INHIBITORS | Acturum Life Science AB (SE) | 2016-06-02 | — | — | WO | disclosed |
| EP-1206429-A2 | STILBENES WITH VASCULAR DAMAGING ACTIVITY | Angiogene Pharmaceuticals Ltd (GB) | 2002-05-22 | — | — | EP | disclosed |
| WO-2001012579-A2 | NEW STILBENES WITH VASCULAR DAMAGING ACTIVITY | ANGIOGENE PHARMACEUTICALS LTD. (GB) | 2001-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10081614-B2 | Bis(sulfonamide) derivatives and their use as mPGES inhibitors | PTGES, PTGS1, PTGES2 | DRD2 3635/4885CYP2C9 79/4885CA12 3297/4885 |
| US-20170313672-A1 | BIS(SULFONAMIDE) DERIVATIVES AND THEIR USE AS MPGES INHIBITORS | PTGES, PTGS1, PTGES2 | DRD2 3635/4885CYP2C9 79/4885CA12 3297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.